Abstract
-
In 2009 the International Stem Cell Banking
Initiative (ISCBI) contributors and the Ethics
Working Party of the International Stem Cell
Forum published a consensus on principles of
best practice for the procurement, cell banking,
testing and distribution of human embryonic
stem cell (hESC) lines for research purposes [1],
which was broadly also applicable to human
induced pluripotent stem cell (hiPSC) lines.
Here, we revisit this guidance to consider what
the requirements would be for delivery of the
early seed stocks of stem cell lines intended for
clinical applications.